Global Alert and Response (GAR)

Hepatitis A


Reference List


Reference List

  1. Churchill's Illustrated Medical Dictionary, New York, Churchill Livingstone, 1989.

  2. Stedman's Medical Dictionary, 26th ed. Baltimore, Williams & Wilkins, 1995.

  3. Ambrosch F et al. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine, 1997, 15(11):1209-1213.

  4. André FE. Approaches to a vaccine against hepatitis A: development and manufacture of an inactivated vaccine. Journal of Infectious Diseases, 1995, 171(Suppl 1):S33-S39.

  5. Barzaga BN. Hepatitis A shifting epidemiology in South-East Asia and China. Vaccine, 2000, 18(Suppl 1(2)):S61-S64.

  6. Battegay M, Gust ID, and Feinstone SM. Hepatitis A virus. In: Mandell GL, Bennett JE, and Dolin R, eds. Principles and Practice of Infectious Diseases, 4th ed. New York, Churchill Livingstone, 1995:1636-1656.

  7. Berge JJ et al. The cost of hepatitis A infections in American adolescents and adults in 1997. Hepatology, 2000, 31(2):469-473.

  8. Burke DS, Graham RR, and Heisey GB. Hepatitis A virus in primates outside captivity. Lancet, 1981, 2:928.

  9. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices. Morbidity and Mortality Weekly Report, 1996, 45(RR15):1-30.

  10. Centers for Disease Control and Prevention. Epidemiology and Prevention of Viral Hepatitis A to E: An Overview. 2000. http://www.cdc.gov./ncidod/diseases/hepatitis/slideset/httoc.htm

  11. Cianciara J. Hepatitis A shifting epidemiology in Poland and Eastern Europe. Vaccine, 2000, 18(Suppl 1(2)):S68-S70.

  12. Clemens R et al. Clinical experience with an inactivated hepatitis A vaccine. Journal of Infectious Diseases, 1995, 171(Suppl 1):S44-S49.

  13. Czeschinski PA, Binding N, and Witting U. Hepatitis A and hepatitis B vaccinations: immunogenicity of combined vaccine and of simultaneously or separately applied vaccines. Vaccine, 2000, 18(11-12):1074-1080.

  14. Emerson SU et al. A simian strain of hepatitis A virus, AGM-27, functions as an attenuated vaccine for chimpanzees. Journal of Infectious Diseases, 1996, 173:592-597.

  15. Hillis WD. An outbreak of infectious hepatitis among chimpanzee handlers at a United States Air Force Base. American Journal of Hygiene, 1961, 73:316-328.

  16. Hollinger FB. An overview of the clinical development of hepatitis A vaccine. Introduction. Journal of Infectious Diseases, 1995, 171(Suppl 1):S1.

  17. Hollinger FB et al. Discussion: who should receive hepatitis A vaccine? A strategy for controlling hepatitis A in the United States. Journal of Infectious Diseases, 1995, 171(Suppl 1):S73-S77.

  18. Hollinger FB and Ticehurst JR. Hepatitis A virus. In: Fields BN, Knipe DM, and Howley PM, eds. Fields Virology, 3rd ed. Philadelphia, Lippincott - Raven, 1996:735-782.

  19. Innis B et al. Protection against hepatitis A by an inactivated vaccine. Journal of American Medical Association, 1994, 271:1328-1334.

  20. Kessler H et al. Hepatitis A and B at the London Zoo. Journal of Infection, 1982, 4:63-67.

  21. Koff RS. Hepatitis A. Lancet, 1998, 341:1643-1649.

  22. Lemon SM. Hepatitis A virus. In: Webster RG and Granoff A, eds. Encyclopedia of Virology, London, Academic Press Ltd, 1994:546-554.

  23. Lemon SM. Type A viral hepatitis: epidemiology, diagnosis, and prevention. Clinical Chemistry, 1997, 43(8(B)):1494-1499.

  24. Lemon SM et al. Genomic heterogeneity among human and nonhuman strains of hepatitis A virus. Journal of Virology, 1987, 61(3):735-742.

  25. Lemon SM and Robertson BH. Current perspectives in the virology and the molecular biology of hepatitis A virus. Seminars in Virology, 1993, 4:285-295.

  26. Loutan L et al. Inactivated virosome hepatitis A vaccine. Lancet, 1994, 343:322-324.

  27. Maiwald H et al. Long-term persistence of anti-HAV antibodies following active immunization with hepatitis A vaccine. Vaccine, 1997, 15(4):346-348.

  28. Mao JS et al. Further evaluation of the safety and protective efficacy of live attenuated hepatitis A vaccine (H2-strain) in humans. Vaccine, 1997, 15(9):944-947.

  29. Mao JS et al. Susceptibility of monkeys to human hepatitis A virus. Journal of Infectious Diseases, 1981, 144(1):55-60.

  30. McMahon BJ et al. A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine. Archives of Pediatrics & Adolescent Medicine, 1996, 150:733-739.

  31. Melnick JL. History and epidemiology of hepatitis A virus. Journal of Infectious Diseases, 1995, 171(Suppl 1):S2-S8.

  32. Niu MT et al. Two-year review of hepatitis A vaccine safety: data from the vaccine adverse event reporting system (VAERS). Clinical Infectious Diseases, 1998, 26:1475-1476.

  33. Poovorawan Y et al. Safety, immunogenicity, and kinetics of the immune response to a single dose of virosome-formulated hepatitis A vaccine in Thais. Vaccine, 1995, 13(10):891-893.

  34. Rajan E, Shattock AG, and Fielding JF. Cost-effective analysis of hepatitis A prevention in Ireland. American Journal of Gastroenterology, 2000, 95(1):223-226.

  35. Robertson BH et al. Antibody response to nonstructural proteins of hepatitis A virus following infection. Journal of Medical Virology, 1993, 40:76-82.

  36. Schulman AN et al. Hepatitis A antigen particles in liver, bile, and stool in chimpanzees. Journal of Infectious Diseases, 1976, 134(1):80-84.

  37. Shapiro CN and Margolis HS. Worldwide epidemiology of hepatitis A virus infection. Journal of Hepatology, 1993, 18(Suppl 2):S11-S14.

  38. Soucie JM et al. Hepatitis A virus infections associated with clotting factor concentrate in the United States. Transfusion, 1998, 38:573-579.

  39. Stapleton JT. Host immune response to hepatitis A virus. Journal of Infectious Diseases, 1995, 171(Suppl 1):S9-S14.

  40. Stapleton JT and Lemon SM. Hepatitis A and hepatitis E. In: Hoeprich PD, Jordan MC, and Ronald AR, eds. Infectious Diseases, 5th ed. Philadelphia, Lippincott Co, 1994:790-797.

  41. Steffen R. Hepatitis A in travelers: the European experience. Journal of Infectious Diseases, 1995, 171(Suppl 1):S24-S28.

  42. Tanaka J. Hepatitis A shifting epidemiology in Latin America. Vaccine, 2000, 18(Suppl 1(2)):S57-S60.

  43. Tormans G, Van Damme P, and Van Doorslaer E. Cost-effectiveness analysis of hepatitis A prevention in travellers. Vaccine, 1992, 10(Suppl 1):S88-S92.

  44. Tufenkeji H. Hepatitis A shifting epidemiology in the Middle East and Africa. Vaccine, 2000, 18(Suppl 1(2)):S65-S67.

  45. Viral Hepatitis Prevention Board. News from the VHPB meeting in St. Julians, Malta. Viral Hepatitis, 1997, 6(1).

  46. Walton J, Barondess JA, and Lock S. The Oxford Medical Companion, Oxford, Oxford University Press, 1994.

  47. Wolfe MS. Hepatitis A and the American traveler. Journal of Infectious Diseases, 1995, 171(Suppl 1):S29-S32.

Share